Joinn Laboratories(China)Co.,Ltd. (603127.SS)
CNY 17.42
(0.87%)
CNY 17.42
(0.87%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 639.51 Million CNY | -47.61% |
| 2022 | 1.37 Billion CNY | 92.21% |
| 2021 | 750.8 Million CNY | 71.17% |
| 2020 | 422.05 Million CNY | 60.09% |
| 2019 | 259.39 Million CNY | 64.13% |
| 2018 | 157.74 Million CNY | 31.43% |
| 2017 | 119.63 Million CNY | 35.74% |
| 2016 | 67.3 Million CNY | 7.04% |
| 2015 | 82.75 Million CNY | -5.7% |
| 2014 | 70.78 Million CNY | 208.82% |
| 2013 | 28.5 Million CNY | 327.62% |
| 2012 | 6.66 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 45.66 Million CNY | -205.0% |
| 2024 Q3 | 108.03 Million CNY | -5.07% |
| 2024 Q2 | -166.42 Million CNY | 145.03% |
| 2023 Q4 | 243.51 Million CNY | -37.47% |
| 2023 FY | - CNY | -47.61% |
| 2023 Q1 | 119.24 Million CNY | -83.94% |
| 2023 Q2 | 2.89 Million CNY | -97.57% |
| 2023 Q3 | 389.44 Million CNY | 13332.49% |
| 2022 Q3 | 71.31 Million CNY | -78.55% |
| 2022 Q2 | 332.45 Million CNY | 222.54% |
| 2022 Q1 | 103.07 Million CNY | -74.72% |
| 2022 FY | - CNY | 92.21% |
| 2022 Q4 | 742.53 Million CNY | 941.17% |
| 2021 Q1 | 105.96 Million CNY | -52.93% |
| 2021 Q3 | 33.62 Million CNY | -51.42% |
| 2021 Q4 | 407.69 Million CNY | 1112.47% |
| 2021 FY | - CNY | 71.17% |
| 2021 Q2 | 69.21 Million CNY | -34.68% |
| 2020 Q3 | 47.19 Million CNY | -25.26% |
| 2020 Q4 | 225.12 Million CNY | 377.02% |
| 2020 FY | - CNY | 60.09% |
| 2020 Q1 | 20.4 Million CNY | -83.92% |
| 2020 Q2 | 63.14 Million CNY | 209.4% |
| 2019 FY | - CNY | 64.13% |
| 2019 Q4 | 126.9 Million CNY | 211.56% |
| 2019 Q3 | 40.73 Million CNY | 15.98% |
| 2019 Q2 | 35.11 Million CNY | 133.18% |
| 2019 Q1 | 15.06 Million CNY | -78.05% |
| 2018 Q3 | 37.5 Million CNY | 79.45% |
| 2018 Q2 | 20.89 Million CNY | 159.95% |
| 2018 Q4 | 68.62 Million CNY | 83.0% |
| 2018 Q1 | 8.03 Million CNY | -84.94% |
| 2018 FY | - CNY | 31.43% |
| 2017 FY | - CNY | 35.74% |
| 2017 Q1 | -9.54 Million CNY | -118.42% |
| 2017 Q2 | 23.73 Million CNY | 348.55% |
| 2017 Q3 | 27.03 Million CNY | 13.89% |
| 2017 Q4 | 53.39 Million CNY | 97.53% |
| 2016 Q3 | 4 Million CNY | 0.0% |
| 2016 Q4 | 51.83 Million CNY | 1195.4% |
| 2016 FY | - CNY | 7.04% |
| 2015 FY | - CNY | -5.7% |
| 2014 FY | - CNY | 208.82% |
| 2013 FY | - CNY | 327.62% |
| 2012 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.11 Billion CNY | 42.577% |
| WuXi AppTec Co., Ltd. | 14.16 Billion CNY | 95.487% |
| Autobio Diagnostics Co., Ltd. | 1.87 Billion CNY | 65.851% |
| Thalys Medical Technology Group Inc. | -23.79 Million CNY | 2787.794% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 1.33 Billion CNY | 51.977% |
| Chemclin Diagnostics Co., Ltd. | 219.33 Million CNY | -191.565% |